Syntheses of novel heterocycles as anticancer agents

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 10, 2005, Pages 3513-3518

  Chauhan, Prem M S ^a,b   Martins, Cristina J A ^a   Horwell, David C ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anticancer; Heterocycles; Pteridine; Pyrimidine; Uracil

Indexed keywords

1 (4 BROMOPHENYL) 2 (4 HYDROXY 6,7 DIMETHYLPTERIDIN 2 YLSULFANYL)ETHANONE; 2 (1H BENZIMIDAZOL 2 YLMETHYLSULFANYL) 6,7 DIMETHYLPTERIDIN 4 OL; 2 (1H BENZIMIDAZOL 2 YLMETHYLSULFANYL)PTERIDIN 4 OL; 2 (2 AMINO 6,7 DIMETHYLPTERIDIN 4 YLAMINO)ETHANOL; 2 (2 BROMOETHYLSULFANYL)PTERIDIN 4 OL; 2 (2 MERCAPTO 6,7 DIMETHYLPTERIDIN 4 YLAMINO)ETHANOL; 2 (3,5 DIMETHYLISOXAZOL 4 YLMETHYLSULFANYL) 6,7 DIMETHYLPTERIDIN 4 OL; 2 (3,5 DIMETHYLISOXAZOL 4 YLMETHYLSULFANYL)PTERIDIN 4 OL; 2 (4 BROMO 1 BENZOYLMETHYLSULFANYL) 6,7 DIMETHYLPTERIDIN 4 OL; 2 (PYRROLIDIN 1 YLETHYLSULFANYL)PTERIDIN 4 OL; 2 (QUINOLIN 2 YLMETHYLSULFANYL)PTERIDIN 4 OL; 4 (2 HYDROXYETHYLAMINO) 6,7 DIMETHYL 1H PTERIDIN 2 ONE; 6,7 DIMETHYL 2 (QUINOLIN 2 YLMETHYLSULFANYL)PTERIDIN 4 OL; ANTINEOPLASTIC AGENT; HETEROCYCLIC COMPOUND; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

EID: 17444377880     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.02.055     Document Type: Article

References (15)

1. M. Kidwai, R. Venkataramanan, R. Mohan, and P. Sapra Curr. Med. Chem. 9 2002 1209 1228
2. J.F. Beattie, G.A. Breault, R.P.A. Ellston, S. Green, P.J. Jewsbury, C.J. Midgley, R.T. Naven, C.A. Minshull, R.A. Pauptit, J.A. Tucker, and J.E. Pease Bioorg. Med. Chem. Lett. 14 2003 2955 2960
3. M.A. Khaled, R.D. Morin, F. Benington, and J.P. Daughery Cancer Chemother. Pharmacol. 13 1984 73 74
4. D.C. Suster, E. Tarnauceanu, D. Ionescu, V. Dobre, and I. Niculescu-Duvaz J. Med. Chem. 21 1978 1162 1165
5. M.J. Berridge Nature 361 1993 315 325
6. J.R.O. Bertino J. Clin. Oncol. 11 1993 5 14
7. B.I. Schaweitzer, A.P. Dicker, and J.R. Bertino FASEB J. 4 1990 2441 2452
8. J.R. Piper, C.A. Johnson, J.A. Maddry, N.D. Malik, J.J. McGuire, G.M. Otter, and F.M. Sirotnak J. Med. Chem. 36 1993 4161
9. W. Gibson, F.T. Boyle, and G.M.F. Bisset J. Med. Chem. 39 1996 73 85
10. A.J. Boulton, and A. Mckillop Compr. Heterocyclic Chem. 3 1984 232 263
11. M.C. Alley, D.A. Scudiero, P.A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, and M.R. Boyd Cancer Res. 48 1988 589 601
12. M.R. Grever, S.A. Schepartz, and B.A. Chabner Semin. Oncol. 19 1992 622 638
13. M.R. Boyd, and K.D. Paull Drug Dev. Res. 34 1995 91 109
14. A. Albert, D.J. Brown, and G. Cheeseman J. Chem. Soc. 1952 4219 4232
15. G. Levin, A. Kalmus, and F. Bergmann J. Org. Chem. 25 1960 1752 1754